This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • Drug Therapy, Other  • Malaria  • Alert me on articles by topic

JAMA. 2007;298:1156.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

MMWR. 2007;56:769-770

On June 21, 2007, CDC's Investigational New Drug Application (IND) for intravenous artesunate went into effect. This IND allows for use of an investigational antimalarial medication (intravenous artesunate) under a protocol entitled "Intravenous Artesunate for Treatment of Severe Malaria in the United States." Intravenous artesunate can be used only under the provisions of this IND protocol because it is not a drug approved by the Food and Drug Administration (FDA). Artesunate is in the class of medications known as artemisinins, which are derivatives from "quing hao," or sweet wormwood plant (Artemisia annua). Only the CDC Drug Service and CDC Quarantine Stations will be permitted to release the medication for use under this IND protocol.

Approximately 1,400 cases of malaria (nearly all imported) are diagnosed in the United States each year; approximately 10% are cases of severe malaria.¹ Intravenous quinidine gluconate, principally used as an antiarrhythmic medicine, . . . [Full Text of this Article]

Patient Eligibility for Investigational Use of Artesunate